American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

PURPLE BIOTECH LTD. (PPBT)

$1.43 +2.88% NASDAQ: PPBT · 15-min delayed

Public · NASDAQ: PPBT
10 employees

Visit website Follow

$2.8MMarket cap

10Employees

PPBTNASDAQ

2015IPO

About PURPLE BIOTECH LTD.

Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: PPBT
Employees: 10
IPO date: Nov 20, 2015
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: PPBT Nasdaq
SEC CIK: 1614744
SIC: 2834 Pharmaceutical Preparations

Embed this company’s badge

Show Purple Biotech Ltd.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/purple-biotech-ltd/"><img src="https://americancompanies.com/badge/purple-biotech-ltd.svg" alt="Purple Biotech Ltd. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow PURPLE BIOTECH LTD. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Market cap: $2.8M

NASDAQ: PPBT

$1.43 +2.88%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.33 $27.75

52-week range

Market cap: $2.8M
Shares outstanding: 1.9M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Nov 20, 2015

Purple Biotech Ltd. (PPBT) Stock Price

Trading 95% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review PURPLE BIOTECH LTD..

Write a review

Newsroom

News about PURPLE BIOTECH LTD.

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress GlobeNewswire Inc. · 2025-12-04 · positive Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification GlobeNewswire Inc. · 2025-10-20 · negative Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants GlobeNewswire Inc. · 2025-09-05 · neutral Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 GlobeNewswire Inc. · 2025-07-23 · positive Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial GlobeNewswire Inc. · 2025-02-18 · positive Purple Biotech Reports Third Quarter 2024 Financial Results GlobeNewswire Inc. · 2024-11-15 · positive

News & sentiment via Polygon.io

FAQ

Purple Biotech Ltd.: frequently asked questions

Is Purple Biotech Ltd. an American company?

Purple Biotech Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Purple Biotech Ltd. publicly traded?

Yes — Purple Biotech Ltd. is a publicly traded company. Its stock trades under the ticker symbol PPBT on the NASDAQ.

What does Purple Biotech Ltd. do?

Purple Biotech Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore